Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Adherence news

Show

From To
Uganda:HIV Patients to Get Rewards for Taking ARVs

Mildmay Uganda and the United States based RAND Corporation yesterday launched a five-year research study of rewarding people living with HIV who take their antiretroviral drugs consistently.

Published
20 April 2018
From
AllAfrica
Researchers ID four types of nonbiomedical PrEP failure

Serota and colleagues describe 14 men who became infected with HIV in their EleMENt study of 300 young BMSM in Atlanta, despite being offered PrEP, along with services to ease access to PrEP uptake. They rightly point out that, in addition to the rare biomedical PrEP failures that receive so much attention at scientific meetings, we should focus our attention on the other “typologies” of PrEP failure that occur once PrEP is offered: low PrEP adherence, PrEP discontinuation, PrEP contemplation without initiation and PrEP refusal.

Published
14 April 2018
From
Healio
ARV stock-outs kill more Ugandans

“Of recent, HIV drug stock-out is adding a lot of misery to us as service providers in the ART clinics because we get very few drugs from National Medical Stores (NMS) which is not enough for our patients. We keep on begging for drugs from nearby health centres. When patients spend long time without taking drugs, they develop resistance,” Dr Peter Andrew Kalema said.

Published
12 April 2018
From
The Observer
Violence a major driver for teens not taking their HIV treatment

Four types of violence were independently associated with adherence – physical abuse by caregivers; witnessing domestic violence; teacher violence; or verbal victimisation by healthcare staff. The researchers comment that violence and victimisation from these sources “evoke a sense of betrayal among adolescents for whom they are hoped-for sources of care and support."

Published
06 April 2018
From
AVERT
Antiretroviral drug levels in hair strongly predict viral suppression

Antiretroviral drug levels in a sample of hair were the strongest predictor of response to HIV treatment, and this method also holds promise for monitoring adherence to pre-exposure

Published
06 March 2018
By
Liz Highleyman
Zambia: HIV deaths on treatment underestimated

People with HIV in Zambia were at least ten times more likely to die in the first two years after starting antiretroviral treatment than European

Published
14 February 2018
By
Keith Alcorn
Communication skills training for healthcare workers improves HIV treatment adherence

People with HIV in Tanzania were more likely to report problems with non-adherence to antiretroviral treatment after their healthcare providers underwent training in patient-centred communication

Published
09 February 2018
By
Keith Alcorn
Generic drugs for HIV treatment may save money, but barriers to prescription make savings elusive

The potential savings from prescribing generic antiretrovirals predicted by economic models may be overstated and numerous barriers need to be overcome to bring down the

Published
07 February 2018
By
Keith Alcorn
Disruptions in PrEP adherence provide insights into intimate partner violence

New study finds strong links between PrEP disruptions and intimate partner violence in Kenya and Uganda. Combined interventions could be key to improving adherence and linking victims to support services.

Published
02 February 2018
From
Avert
Long-acting injectable ARVs are convenient and private, study participants report

HIV-positive people who took injectable cabotegravir + rilpivirine every four or eight weeks as antiretroviral therapy found it more convenient and discreet than daily pills, also feeling

Published
17 January 2018
By
Roger Pebody
← First12345...40Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.